ClinicalTrials.gg
Status unknownNCT05290350PostCoV2OSAUpdated Apr 6, 2022

Long COVID-19 Fatigue and Obstructive Sleep Apnea

An observational study in Long COVID, Fatigue and Obstructive Sleep Apnea of Adult, sponsored by Centro Hospitalar Universitario do Algarve. Status unknown at 12 sites in Portugal. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-04-06.

Sponsored by Centro Hospitalar Universitario do Algarve · Observational

How we know

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Identify the relationship of obstructive sleep apnea (OSA) prevalence with post-COVID-19 fatigue that remains at least six months after acute disease

Read the detailed description

The presence of fatigue symptoms up to 6-7 months after acute COVID-19 disease, similar to myalgic encephalomyelitis/chronic fatigue syndrome, also observed after other viral infections, have been reported as the most frequent post-COVID-19 symptom (Townsend et al., 2020).

There is a physiological plausibility for OSA being a causal factor to COVID-19 morbidity and fatigue symptoms by nocturnal hypoxemia, exacerbating or causing endothelial dysfunction, inflammation, oxidative stress, microaspiration and cardiac dysfunction. OSA activates the renin-angiotensin-aldosterone system (RAAS) and angiotensin-converting enzyme-2 (ACE2), which is the SARS-CoV-2 entry receptor in the cells (Miller et al., 2021).

In this study we will identify the prevalence of OSA and it's relation with post-COVID-19 fatigue that remains for at least six month after the acute disease, in patients that attend the post-COVID-19 Out Patients Hospital Clinics. It will be studied also the relation between fatigue and vaccination status, nocturnal hypoxemia, day time sleepness and the acute COVID-19 severity.

Data collection will be performed by a questionnaire administered by qualified clinical study staff (i.e., by physicians who conduct the post-COVID-19 medical consultation).

Demographic, clinical data and clinical research forms will be collected between 6-7th month after the diagnosis of COVID-19 (t1) and 9 months later (t2).

Fatigue will be assessed using the Chalder fatigue scale - CFQ-11 (Chalter et al., 1993).

The evaluation of OSA related daytime sleepiness will be measured using the Epworth Sleepiness Scale - ESS (Johns, 1991). The OSA diagnosis will be performed using portable monitoring device type III (in-home polygraphy), between 6-7th month after the diagnosis of COVID-19 (t1).

02

Conditions studied

  • Long COVID
  • Fatigue
  • Obstructive Sleep Apnea of Adult

Keywords

  • Post-COVID-19 fatigue Sleep Apnea SARS-CoV-2 Vaccines
03

In context

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

This study's planned enrollment of 300 is above the median of 150 across 173 observational studies indexed under Post-Acute COVID-19 Syndrome.

Browse Post-Acute COVID-19 Syndrome studies →

Lead sponsor

Centro Hospitalar Universitario do Algarve is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted in twelve Portuguese Hospitals, Universitary and District, in which a follow-up post-COVID-19 medical consultation has been implemented All patients that attend the follow-up post COVID-19 consultation will be invited to participate in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

(1) ≥18 years; (2) previous COVID-19 at least six months before the initial study protocol evaluation; (3) persistent symptoms after cure criteria defined by WHO; (4) patients who attend the post-COVID-19 follow-up consultation of the study centers. (5) SARS-CoV-2 infection confirmed by a positive real-time reverse-transcription polymerase chain reaction on a nasopharyngeal swab (6) patients who agree to sign the Written (following the ethics committee protocol).

Exclusion criteria

Exclusion Criteria:

(1) patients who had a concomitant neurological disorder that could increase OSA risk (such as stroke, Parkinson disease, or amyotrophic lateral sclerosis); (2) patients who were on invasive mechanical ventilation. (3) patients with persistent fatigue symptoms,6 months before SARS-CoV-2 infection (4) patients without SARS-CoV-2 positive real-time reverse-transcription polymerase chain reaction on a nasopharyngeal swab

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • OSA Cohort

    Patients With post COVID-19 condition and OSA

    Other: OSA

  • Control Cohort

    Patients With post COVID-19 condition without OSA

Interventions

  • OtherOSA

    EXPOSURE TO OBSTRUCTIVE SLEEP APNEA

06

What researchers measure

Primary outcomes

  1. post-COVID-19 long term fatigue and OSA

    Evaluate if untreated OSA is associated with post COVID-19 long term fatigue.

    Time frame: 6 - 7 months

Secondary outcomes

  1. post-COVID-19 long term fatigue and daytime sleepiness

    Evaluate if daytime sleepiness is associated with post COVID-19 long term fatigue.

    Time frame: 6 - 9 months

  2. post-COVID-19 long term fatigue and nocturnal hypoxemia

    Evaluate if nocturnal hypoxemia is associated with post COVID-19 long term fatigue

    Time frame: 6 - 7 months

  3. post-COVID-19 long term fatigue and severity of acute COVID-19

    Evaluate if severity of acute COVID-19 is associated with post COVID-19 long term fatigue

    Time frame: 6 - 9 months

  4. post-COVID-19 long term fatigue and vaccination status

    Study the relation between vaccination status and post-COVID-19 long term fatigue

    Time frame: 6 - 9 months

  5. Long COVID-19 and OSA impact in quality of life

    Study the impact of Long COVID-19 with untreated OSA in quality of life

    Time frame: 6 - 7 months

07

Study locations

10 of 12 sites recruiting
  • Hospital Particular de Alvor
    Alvor, 8500-322, Portugal
    Recruiting
  • Hospital de Faro (Chua)
    Faro, 800-386, Portugal
    Recruiting
  • Hospital da Luz Guimaraes (HLG)
    Guimarães, 4835-23, Portugal
    Recruiting
    • Maria Jose Guimaraes, MD · Contactzezaguimaraes@gmail.com · +351253420300
    • Maria Jose Guimaraes · Principal investigator
  • Hospital de Santo Andre (Chl)
    Leiria, 2410-197, Portugal
    Recruiting
  • Hospital Da Luz Lisboa
    Lisboa, 1500-650, Portugal
    Not yet recruiting
  • Hospital de Santa Maria (CHULN)
    Lisboa, 1649-028, Portugal
    Recruiting
  • Hospital Beatriz Angelo (Hba)
    Loures, 2674-514, Portugal
    Not yet recruiting
  • Hospital de Portimao (Chua)
    Portimao, 8500-338, Portugal
    Recruiting
    • Ligia Pires, MD · Contactalves1029@hotmail.com · 282450300
    • Tania Fatal · Contacttaniafatal@hotmail.com · 282450300
    • Ligia Pires, MD · Principal investigator
    • Ines Simoes, MD · Sub investigator
    • Catia Saraiva, MD · Sub investigator
    • Ines Belchior, MD · Sub investigator
    • Tania Fatal, MD · Sub investigator
    • Catarina Possacos, MD · Sub investigator
  • Hospital Sao Joao (Chusj)
    Porto, 4200-319, Portugal
    Recruiting
    • Marta Drummond, Prof · Contactmarta.drummond@gmail.com · +351225512100
    • Renato Silva · Contactrenato.ivos@gmail.com · +351225513600
    • Marta Drummond, Prof · Principal investigator
    • Margarida Tavares, Prof · Sub investigator
  • Hospital de Sao Sebastiao (Chedv)
    Santa Maria Da Feira, 4520-211, Portugal
    Recruiting
  • Centro Hospitalar de Setubal (Chs)
    Setubal, 2910-549, Portugal
    Recruiting
  • Centro Hospitalar De Trás-Os-Montes E Alto Douro (CHTMAD)
    Vila Real, 5000-508, Portugal
    Recruiting
    • Bebiana Conde, Prof · Contactbebianaconde@gmail.com · 259300500
    • Bebiana Conde, Prof · Principal investigator
08

References and documents

Publications

  • Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147-53. doi: 10.1016/0022-3999(93)90081-p. PubMed 8463991 ↗
  • Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi: 10.1093/sleep/14.6.540. PubMed 1798888 ↗
  • Miller MA, Cappuccio FP. A systematic review of COVID-19 and obstructive sleep apnoea. Sleep Med Rev. 2021 Feb;55:101382. doi: 10.1016/j.smrv.2020.101382. Epub 2020 Sep 8. PubMed 32980614 ↗
  • Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, O'Connor L, Leavy D, O'Brien K, Dowds J, Sugrue JA, Hopkins D, Martin-Loeches I, Ni Cheallaigh C, Nadarajan P, McLaughlin AM, Bourke NM, Bergin C, O'Farrelly C, Bannan C, Conlon N. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020 Nov 9;15(11):e0240784. doi: 10.1371/journal.pone.0240784. eCollection 2020. PubMed 33166287 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Nov 2022, 8 months after the start.

Of 97 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 8 months is below that.

Counting every sponsor, half of 104 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2022
First posted
Mar 22, 2022
StartActual
Mar 10, 2022
Primary completionEst.
Nov 30, 2022
CompletionEst.
Jan 30, 2023
Last update
Apr 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05290350
Lead sponsor
Centro Hospitalar Universitario do Algarve
Collaborators
Sociedade Portuguesa de Pneumologia, Universidade do Algarve, Universidade do Porto, Center for Health Technology and Services Research, Linde Health Care
Responsible party
Ligia Pires (Principal Investigator, Centro Hospitalar Universitario do Algarve) — Principal investigator
First posted
Mar 22, 2022
Start date
Mar 10, 2022
Primary completion
Nov 30, 2022 (estimated)
Completion
Jan 30, 2023 (estimated)
Last update
Apr 6, 2022

Study contacts

Ligia Pires
Contact
alves1029@hotmail.com
+351282450300 ext. 43168
Tania Fatal
Contact
taniafatal@hotmail.com
+351282450300 ext. 35427
Ligia Pires
study chair · Centro Hospitalar Universitario do Algarve

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion